Grace Announces Silica-based Drug Delivery Platform

October 8, 2015
Pharmaceutical Technology Editors

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-11-04-2015, Volume 11, Issue 11

Grace and Formac Pharmaceuticals have announced SilSol 6035 Mesoporous Silica Gel, the first silica in the Grace silica-based drug delivery platform. The silica gel is the result of a multi-year collaboration between the companies.The platform was engineered to offer a new drug delivery option for APIs with poor aqueous solubility (BCS class 2 compounds), Grace reports and combines the company’s expertise in mesoporous silica gel and novel application methods to accelerate the screening and development of stable, amorphous-based systems.

Grace and Formac Pharmaceuticals have announced SilSol 6035 Mesoporous Silica Gel, the first silica in the Grace silica-based drug delivery platform. The silica gel is the result of a multi-year collaboration between the companies.

The platform was engineered to offer a new drug delivery option for APIs with poor aqueous solubility (BCS class 2 compounds), Grace reports and combines the company’s expertise in mesoporous silica gel and novel application methods to accelerate the screening and development of stable, amorphous-based systems.

The platform is suitable for NCE, life cycle management, reformulations, and repositioning; it can be used for a range of compounds; can generate stable formulations; and can be introduced into established manufacturing units.

The platform conforms to global monographs, is scalable from grams to tons quantities under excipient GMP manufacture; and is listed on the FDA inactive ingredient database, Grace reports.

Grace is exhibiting at CPhI Worldwide 2015, stand 7A24, Oct. 13–15, in Madrid, Spain.

Source: Grace